Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. HYPR
HYPR logo

HYPR Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
1.600
Open
1.600
VWAP
1.56
Vol
710.98K
Mkt Cap
154.86M
Low
1.530
Amount
1.11M
EV/EBITDA(TTM)
--
Total Shares
99.27M
EV
131.18M
EV/OCF(TTM)
--
P/S(TTM)
9.11
Hyperfine, Inc. is a health technology company. The Company is engaged in providing patient care globally through artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. Its Swoop Portable MR Imaging System (Swoop system) produces images at a lower magnetic field strength than conventional magnetic resonance imaging (MRI) scanners. Its Swoop system is designed to transform brain MR for the patient, the clinician and the provider, enabling a highly differentiated experience for patients, timely imaging for clinicians, and favorable economics for hospital administrators. The Swoop system is a portable ULF MRI device for producing images that display the internal structures of the head where full diagnostic examination is not clinically practical. The Swoop system is FDA-cleared for brain imaging of patients of all ages. The Swoop system is commercially available in a select number of international markets.
Show More

Events Timeline

(ET)
2026-05-12
16:50:00
Hyperfine Files to Sell 1.08M Shares of Class A Common Stock
select
2026-05-12
16:10:00
Hyperfine Reports Q1 Revenue of $3.9M, Exceeds Expectations
select
2026-05-12
16:10:00
Management Expects 2026 Cash Burn of $26M-$28M
select
2026-04-29 (ET)
2026-04-29
08:20:00
Hyperfine and AIIMS New Delhi Launch Clinical Use of Swoop Portable MRI System
select

News

seekingalpha
8.5
05-26seekingalpha
Hyperfine Expected to Join Russell 2000 Index
  • Index Inclusion Expected: Hyperfine (HYPR) is anticipated to join the Russell 2000 and Russell 3000 indexes after the U.S. market closes on June 26, based on a preliminary list published by FTSE Russell on May 22, indicating increased recognition in the capital markets.
  • Strategic Progress: CEO Maria Sainz stated that this inclusion reflects advancements in the company's commercial strategy and the adoption of its portable MRI technology, suggesting enhanced growth potential moving forward.
  • Strong Financial Performance: In its Q1 2026 earnings report, Hyperfine reported revenue of $3.90 million, exceeding market expectations by $0.37 million, while the GAAP EPS of -$0.09 indicates a solid gross margin of 50%-55%, showcasing robust profitability.
  • Future Revenue Targets: Hyperfine has set a revenue target of $20 million to $22 million for 2026, demonstrating confidence in future growth and reflecting its ongoing innovation and market expansion capabilities in the healthcare technology sector.
Newsfilter
3.5
05-22Newsfilter
Portable MRI Study Shows Efficiency in Emergency Care
  • Clinical Trial Results: At the 2026 Annual Meeting of the Society for Academic Emergency Medicine, Hyperfine presented results from the PRIME study, demonstrating that portable MRI significantly enhances imaging efficiency in emergency departments by reducing the median time from imaging order to scan start from 7.76 hours to 1.28 hours, a difference of 6.35 hours, highlighting its potential value in urgent situations.
  • Critical Pathology Detection: Among completed scans, 18.6% revealed critical pathologies such as acute ischemic stroke and mass lesions, which were successfully detected by portable MRI and confirmed by conventional MRI, underscoring its importance in rapid diagnosis.
  • Workflow Optimization: The study indicates that portable MRI can be integrated into emergency department workflows more swiftly, alleviating patient boarding delays associated with waiting for conventional MRI, thereby enhancing overall care efficiency for emergency teams.
  • Future Development Potential: Hyperfine's Swoop® system, by providing faster imaging services, may transform emergency medicine, assisting clinicians in accessing actionable imaging information sooner and advancing the field of emergency neuroimaging.
seekingalpha
9.5
05-13seekingalpha
Hyperfine, Inc. Reports Q1 2026 Earnings Highlights
  • Significant Revenue Growth: Hyperfine reported Q1 2026 revenue of $3.9 million with a gross margin of 51%, demonstrating effective execution in both growth and cost control, thereby enhancing its competitive position in the market.
  • International Expansion Progress: The company obtained CE and UKCA marks for its next-generation Swoop system and DWI Optive AI software, with plans to launch in Europe in Q3, further broadening its international business footprint.
  • Increased Product Adoption: The advanced DWI Optive AI software is now implemented in most scanners, with unit sales rising from 6 to 10 compared to the prior year, indicating accelerated penetration in the large customer market.
  • Stable Financial Outlook: Management reiterated full-year revenue expectations between $20 million and $22 million, with gross margins projected to remain between 50% and 55%, and cash burn controlled at $26 million to $28 million, reflecting confidence in future performance.
CNBC
6.0
04-29CNBC
Latest Wall Street Rating Updates
  • Starbucks Rating Maintained: Morgan Stanley reiterates its overweight rating on Starbucks, indicating that the ongoing debate about the company's earnings power reflects an improving narrative that may attract more investor interest.
  • Robinhood Outlook Positive: Bernstein maintains an outperform rating on Robinhood, noting that HOOD stock marked a bottom in Q1 and has started strong in April, suggesting increasing market confidence in its future.
  • CoreWeave Price Target Raised: Wells Fargo raises CoreWeave's price target from $125 to $135, believing that the company's leading position in AI infrastructure will allow it to benefit as demand continues to outpace supply.
  • Telecom Argentina Upgrade: JPMorgan upgrades Telecom Argentina from neutral to overweight, expecting substantial benefits from market consolidation as the antitrust review of its acquisition of Telefonica Argentina nears completion.
Newsfilter
8.5
04-29Newsfilter
AIIMS New Delhi Launches Portable MRI System for Clinical Use
  • Clinical Use Initiated: AIIMS New Delhi, in partnership with Radiosurgery Global India, has begun clinical use of the Hyperfine Swoop® portable MRI system, marking a significant milestone in neurological care that is expected to greatly enhance imaging efficiency for emergency and critically ill patients.
  • Significant Technical Advantages: The Swoop® system eliminates the need for dedicated rooms or patient transport, allowing for bedside brain imaging in ICUs and trauma centers, thereby removing the risks associated with traditional MRI transport and improving diagnostic speed and patient outcomes.
  • Broad Clinical Impact: This system addresses unmet clinical needs across neurology, trauma care, and critical care, particularly in providing rapid assessment for acute stroke and traumatic brain injury, delivering essential imaging support at critical moments.
  • Platform for Research and Innovation: The deployment at AIIMS New Delhi establishes a foundation for clinical research, with plans to document outcomes and advance the adoption of portable MRI in India, enhancing the country's role in the global brain imaging landscape.
PRnewswire
7.5
03-27PRnewswire
Heart Disease Crisis Fuels AI Diagnostic Platforms
  • Economic Burden of Heart Disease: Heart disease costs the European Union over €282 billion annually and claims 1.7 million lives, driving institutional capital to rapidly invest in scalable AI diagnostic platforms, highlighting the urgent market demand for innovative healthcare solutions.
  • Growth of AI Medical Devices: The FDA has approved over 1,200 AI medical devices, with cardiovascular applications emerging as the second largest category, indicating a strong alignment between regulatory support and clinical needs, providing a favorable environment for AI-driven medical technologies.
  • Remote Healthcare Collaboration: VentriPoint Diagnostics is partnering with First Light Health to deliver AI cardiac diagnostics in remote Canadian communities, utilizing the VMS+™ system to enable local providers to collaborate with central specialists, significantly enhancing healthcare accessibility in underserved areas.
  • Potential for Technological Expansion: VentriPoint's VMS+™ system converts standard 2D echocardiograms into 3D volumetric images with accuracy comparable to cardiac MRI, which is expected to drive widespread adoption in underserved communities globally, addressing critical gaps in heart disease diagnosis.
Wall Street analysts forecast HYPR stock price to rise
1 Analyst Rating
Wall Street analysts forecast HYPR stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
2.00
Averages
2.00
High
2.00
Current: 0.000
sliders
Low
2.00
Averages
2.00
High
2.00
B. Riley
Yuan Zhi
NULL
to
Buy
upgrade
$2
AI Analysis
2026-05-13
Reason
B. Riley
Yuan Zhi
Price Target
$2
AI Analysis
2026-05-13
upgrade
NULL
to
Buy
Reason
B. Riley analyst Yuan Zhi raised the firm's price target on Hyperfine to $2 from $1.60 and keeps a Buy rating on the shares.
BTIG
Buy
initiated
$2
2026-04-29
Reason
BTIG
Price Target
$2
2026-04-29
initiated
Buy
Reason
BTIG initiated coverage of Hyperfine with a Buy rating and $2 price target. The company's Swoop System enables point-of-care brain MRI at the bedside, expanding access to MRI imaging by eliminating the need for a shielded room, specialized staff, and patient transport, and the next-generation Swoop V2, cleared in May 2025, paired with the 11th-generation Optive AI software release in December 2025, offers a significant step forward in image quality and clinical utility, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for HYPR
Unlock Now

Valuation Metrics

The current forward P/E ratio for Hyperfine Inc (HYPR.O) is 0.00, compared to its 5-year average forward P/E of -1.96. For a more detailed relative valuation and DCF analysis to assess Hyperfine Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.96
Current PE
0.00
Overvalued PE
-0.78
Undervalued PE
-3.13

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.74
Current EV/EBITDA
-2.10
Overvalued EV/EBITDA
1.07
Undervalued EV/EBITDA
-2.56

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
7.31
Current PS
6.04
Overvalued PS
15.68
Undervalued PS
-1.07

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

take me to stock radar
Intellectia · 53 candidates
Region: USPrice: $1.00 - $30.00Volume: >= 1,000,000Price Change Pct: $-25.00 - $25.00Relative Vol: >= 2List Exchange: XNYS, XNAS
Ticker
Name
Market Cap$
top bottom
SATL logo
SATL
Satellogic Inc
729.00M
HUYA logo
HUYA
HUYA Inc
1.01B
GNTA logo
GNTA
Genenta Science SPA
30.70M
ATOM logo
ATOM
Atomera Inc
105.50M
BAER logo
BAER
Bridger Aerospace Group Holdings Inc
173.85M
UROY logo
UROY
Uranium Royalty Corp
683.86M

Whales Holding HYPR

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Hyperfine Inc (HYPR) stock price today?

The current price of HYPR is 1.56 USD — it has decreased -2.5

What is Hyperfine Inc (HYPR)'s business?

Hyperfine, Inc. is a health technology company. The Company is engaged in providing patient care globally through artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. Its Swoop Portable MR Imaging System (Swoop system) produces images at a lower magnetic field strength than conventional magnetic resonance imaging (MRI) scanners. Its Swoop system is designed to transform brain MR for the patient, the clinician and the provider, enabling a highly differentiated experience for patients, timely imaging for clinicians, and favorable economics for hospital administrators. The Swoop system is a portable ULF MRI device for producing images that display the internal structures of the head where full diagnostic examination is not clinically practical. The Swoop system is FDA-cleared for brain imaging of patients of all ages. The Swoop system is commercially available in a select number of international markets.

What is the price predicton of HYPR Stock?

Wall Street analysts forecast HYPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HYPR is2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Hyperfine Inc (HYPR)'s revenue for the last quarter?

Hyperfine Inc revenue for the last quarter amounts to 3.90M USD, increased 82.64

What is Hyperfine Inc (HYPR)'s earnings per share (EPS) for the last quarter?

Hyperfine Inc. EPS for the last quarter amounts to -0.09 USD, decreased -25.00

How many employees does Hyperfine Inc (HYPR). have?

Hyperfine Inc (HYPR) has 102 emplpoyees as of May 31 2026.

What is Hyperfine Inc (HYPR) market cap?

Today HYPR has the market capitalization of 154.86M USD.